Get the Stockscreener App
88.42
0.75%
-0.665
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $88.42, with a volume of 498.72K.
It is down -0.75% in the last 24 hours and up +4.60% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$89.09
Open:
$88.27
24h Volume:
498.72K
Relative Volume:
0.11
Market Cap:
$274.24B
Revenue:
$58.07B
Net Income/Loss:
$9.40B
P/E Ratio:
29.36
EPS:
3.0113
Net Cash Flow:
$8.49B
1W Performance:
+8.96%
1M Performance:
+4.60%
6M Performance:
+28.24%
1Y Performance:
+35.63%
1-Day Range:
$88.10
$88.50
1-Week Range:
$83.37
$89.31
52-Week Range:
$61.24
$89.31
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
88.42 | 271.24B | 58.07B | 9.40B | 8.49B | 3.0113 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
Will AstraZeneca PLC (ZEG) stock outperform small cap peersJuly 2025 Earnings & Trade Opportunity Analysis - newser.com
Is AstraZeneca PLC (ZEG) stock undervalued historicallyQuarterly Profit Review & Step-by-Step Trade Execution Guides - newser.com
Is AstraZeneca PLC (ZEG) stock positioned for digital growth eraJuly 2025 Fed Impact & Weekly Setup with ROI Potential - newser.com
Can AstraZeneca PLC (Common Stock) (ZEGA) stock surprise with quarterly resultsJuly 2025 Update & Technical Buy Zone Confirmation - newser.com
AstraZeneca impresses with resistant hypertension data at AHA 2025 - BioCentury
FTSE 100 closes at record high on rate cut bets; AstraZeneca shines - MarketScreener
Will AstraZeneca PLC Depositary Receipt continue its uptrendQuarterly Portfolio Report & Expert Approved Momentum Trade Ideas - newser.com
AstraZeneca hits record high, cements lead as UK's biggest stock - MarketScreener
Unnatural Amino Acids Market to Reach US$ 5.03 Billion By 2032 Driven by Advances in Drug Discovery, Biologics and Protein Engineering - GlobeNewswire Inc.
How AstraZeneca PLC (Common Stock) (ZEGA) stock compares with top peersPortfolio Value Summary & Growth Focused Stock Pick Reports - newser.com
Is AstraZeneca PLC (Common Stock) (ZEGA) stock a top pick for value investors2025 Market Overview & Free Accurate Trade Setup Notifications - newser.com
What market sentiment indicators show for Precidian ETFs Trust AstraZeneca PLC stockJuly 2025 Levels & Reliable Momentum Entry Alerts - newser.com
How to build a custom watchlist for AstraZeneca PLC Depositary ReceiptForecast Cut & Precise Buy Zone Identification - newser.com
AstraZeneca Soars on Positive Trial Results for Hypertension Drug and Strong Earnings - NAI500
Why AstraZeneca Stock Was a Winner Today - The Globe and Mail
AstraZeneca PLC ADR outperforms market on strong trading day - MarketWatch
Why AstraZeneca Stock Was a Winner Today - The Motley Fool
Will AstraZeneca PLC (ZEG) stock test record highs in 2025Chart Signals & Safe Capital Investment Plans - newser.com
AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial - Benzinga
Astrazeneca CEO Pascal Soriot gifts over 136,000 shares to family members - Investing.com
[6-K] ASTRAZENECA PLC Current Report (Foreign Issuer) | AZN SEC FilingForm 6-K - Stock Titan
AstraZeneca stock hits 52-week high at 86.57 USD - Investing.com
REGAstraZeneca PLCDirector/PDMR Shareholding - TradingView
AstraZeneca stock hits 52-week high at 86.57 USD By Investing.com - Investing.com UK
ASTRAZENECA : DZ Bank remains Neutral - MarketScreener
AstraZeneca news: surges on FDA orphan drug win and strong Phase III trial results - Traders Union
Technical signs of recovery in AstraZeneca PLC Depositary ReceiptWeekly Gains Summary & Smart Money Movement Alerts - newser.com
AstraZeneca (AZN) Earns FDA Orphan Drug Status for Leukemia Trea - GuruFocus
ASTRAZENECA : Receives a Buy rating from Bernstein - MarketScreener
Astrazeneca Says Hypertension Drug Meets Main, Secondary Goals in Phase 3 Study - MarketScreener
AstraZeneca stock price target raised to $87 from $85 at Leerink Partners - Investing.com UK
Why AstraZeneca PLC (ZEG) stock stays on top picksWeekly Trend Report & Proven Capital Preservation Tips - newser.com
Will AstraZeneca PLC Depositary Receipt stock benefit from sector rotationQuarterly Profit Summary & Weekly Top Performers Watchlists - newser.com
AstraZeneca PLC Depositary Receipt stock chart pattern explainedPortfolio Update Summary & Real-Time Chart Pattern Alerts - newser.com
AstraZeneca bolsters obesity portfolio with muscle‑preserving buy - European Biotechnology Magazine
ASTRAZENECA : JP Morgan reaffirms its Buy rating - MarketScreener
Published on: 2025-11-09 22:51:40 - newser.com
AstraZeneca (AZN) Announces Successful Phase III Trial Results f - GuruFocus
AstraZeneca (AZN) shows 14.0 mmHg 24-hour drop with Baxdrostat in resistant hypertension - Stock Titan
Is Precidian ETFs Trust AstraZeneca PLC stock safe for risk averse investorsMarket Activity Summary & Real-Time Sentiment Analysis - newser.com
AstraZeneca PLC 2025 Q3ResultsEarnings Call Presentation (NASDAQ:AZN) 2025-11-08 - Seeking Alpha
AstraZeneca PLC (NASDAQ:AZN) Q3 2025 Earnings Call Transcript - MSN
AstraZeneca PLC (AZN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Astrazeneca PLC (AZN) Stock forecasts - Yahoo Finance UK
AstraZeneca Earnings: Momentum Continues Across Growth Franchises - Morningstar Canada
AstraZeneca seals obesity deal as Pfizer-Novo Nordisk battle for Metsera - MarketScreener
Institutional scanner results for AstraZeneca PLC Depositary ReceiptTrade Risk Summary & Technical Buy Zone Confirmations - newser.com
Astrazeneca PLC (AZN) Stock Forecasts - Yahoo Finance
AstraZeneca (AZN) Warns UK on Drug Spending Risks - GuruFocus
AstraZeneca Says Fasenra Delayed Disease Worsening in Late-Stage Trial for Hypereosinophilic Syndrome - MarketScreener
AstraZeneca’s FASENRA shows positive results in rare disease trial By Investing.com - Investing.com UK
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):